The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | NAPOLI-3: first-line NALIRIFOX in metastatic pancreatic ductal adenocarcinoma
Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, presents findings from the Phase III NAPOLI-3 trial (NCT04083235), which compared liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) to nab-paclitaxel with gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma. Patients receiving NALIRIFOX demonstrated superior overall survival and progression-free survival, providing a promising first-line treatment for a group of patients with limited options. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, the NAPOLI-3 trial was a randomized Phase III trial comparing two regimens in metastatic pancreatic cancer. One is one of the standard regimens for some time, which was gemcitabine and nab-paclitaxel, and the other one was a NALIRIFOX, which is a combination of liposomal irinotecan, oxaliplatin, and infusional 5-FU. And so the study compared head to head which one would produce a better overall survival, in which one patients would live longer...
Yeah, the NAPOLI-3 trial was a randomized Phase III trial comparing two regimens in metastatic pancreatic cancer. One is one of the standard regimens for some time, which was gemcitabine and nab-paclitaxel, and the other one was a NALIRIFOX, which is a combination of liposomal irinotecan, oxaliplatin, and infusional 5-FU. And so the study compared head to head which one would produce a better overall survival, in which one patients would live longer. The study showed the NALIRIFOX regimen improved overall survival over gemcitabine nab-paclitaxel. And it was about 770 patients total. And so with a statistically significant p-value and hazard ratio, the NALIRIFOX regimen improved overall survival, progression-free survival compared to gemcitabine nab-paclitaxel.
Read more...
